Sanofi (SNY) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi showcases the effectiveness of their infant RSV vaccine, Beyfortus, at IDWeek 2024, with data demonstrating over 80% real-world effectiveness in preventing disease and hospitalization. Beyfortus, which is approved in several regions including the US and EU, is designed to protect all infants through their first RSV season, with new manufacturing lines established to meet global demand.
For further insights into SNY stock, check out TipRanks’ Stock Analysis page.